公司资料
RXDX 股价、新闻与催化剂
- 股票代码:
- RXDX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for RXDX.
公司概览
业务概览
Prometheus Biosciences was an immunology-focused biotechnology company centered on precision medicine for inflammatory bowel disease before being acquired by Merck. Its story was built around translating biomarker-driven biology into targeted treatments.
所在地与行业分类
Prometheus was headquartered in the United States and traded on NASDAQ before the acquisition. It sat in immunology and precision biotechnology.
商业模式特征
The company’s value was driven by clinical readouts, biomarker strategy, and the potential to create a differentiated treatment path in inflammatory disease. Investors watched data quality, target validation, and the strategic interest in its platform.
生物医药行业定位
Prometheus was a premium precision-immunology biotech and one of the more compelling catalyst-driven names of its era. Since it has been acquired, it is now part of biotech M&A history rather than the live public-company universe.
未来催化剂
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。